A Step Forward in the Fight Against Dementia—Are We There Yet?-Reference-Cited by-同舟云学术

A Step Forward in the Fight Against Dementia—Are We There Yet?

Published:2023-05-01 Issue:5 Volume:80 Page:429
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Wolk David A.¹,Rabinovici Gil D.²³,Dickerson Bradford C.⁴

Affiliation:

1. Penn Alzheimer’s Disease Research Center, Perelman School of Medicine, Department of Neurology, University of Pennsylvania, Philadelphia

2. Weill Institute for Neurosciences, Memory and Aging Center, Alzheimer’s Disease Research Center, Department of Neurology, University of California, San Francisco, San Francisco

3. Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco

4. Frontotemporal Disorders Unit, Alzheimer’s Disease Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston

Abstract

This Viewpoint reports on the results of the Clarity AD trial, a phase 3 randomized clinical trial of lecanemab for patients with early Alzheimer disease, in which lecanemab’s clinical efficacy was demonstrated using well-established outcome measures.

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2802273/jamaneurology_wolk_2023_vp_230001_1683210077.13286.pdf

Reference7 articles.

1. Lecanemab in early Alzheimer’s disease.;van Dyck;N Engl J Med,2023

2. Donanemab in early Alzheimer’s disease.;Mintun;N Engl J Med,2021

3. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease.;Budd Haeberlein;J Prev Alzheimers Dis,2022

4. Impact of multiple pathologies on the threshold for clinically overt dementia.;Kapasi;Acta Neuropathol,2017

5. Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies.;Boyle;Ann Neurol,2019

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease;CNS Drugs;2024-06-05

2. Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer’s disease;Alzheimer's Research & Therapy;2024-02-29

3. The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond;Alzheimer's Research & Therapy;2024-02-16

4. Feasibility of Identifying Factors Related to Alzheimer’s Disease and Related Dementia in Real-World Data;2024-02-13

5. Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease;Neurology;2023-11-07